Related Experiment Video
Updated: Jun 7, 2026
08:38
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
Prenatal exposure to mycophenolate mofetil: an updated estimate
Chagit Klieger-Grossmann1, David Chitayat, Sharon Lavign
1Motherisk Program, The Hospital for Sick Children, Toronto ON, Canada.
Journal of Obstetrics and Gynaecology Canada : JOGC = Journal D'Obstetrique Et Gynecologie Du Canada : JOGC
|November 6, 2010
Summary
Mycophenolate mofetil (MMF) use in pregnancy may pose risks, but prospective data suggests the absolute teratogenic risk might be lower than previously thought. Close monitoring and diagnostic imaging are recommended for exposed pregnancies.
Area of Science:
- Pharmacology
- Teratology
- Reproductive Medicine
Background:
- Mycophenolate mofetil (MMF) is a key immunosuppressant for transplant recipients and autoimmune diseases.
- Case reports indicate MMF exposure during pregnancy may cause congenital malformations.
- Unplanned pregnancies necessitate a clear understanding of MMF's teratogenic potential.
Purpose of the Study:
- To prospectively evaluate the teratogenic risk of Mycophenolate mofetil (MMF) exposure during pregnancy.
- To update the understanding of MMF's safety profile in pregnant women.
Main Methods:
- Prospective cohort study utilizing the Organization of Teratology Information Specialists (OTIS) network.
- Identification and follow-up of pregnant women exposed to MMF during embryogenesis.
- Data collection on pregnancy outcomes, including malformations in live births.
Main Results:
- Ten pregnancies exposed to MMF during embryogenesis were identified.
- Four miscarriages and one elective abortion occurred.
- None of the five live births exhibited congenital malformations.
- The observed malformation rate may be lower than suggested by initial case reports.
Conclusions:
- The absolute teratogenic risk of Mycophenolate mofetil (MMF) may be lower than previously estimated from case reports.
- Specific MMF-associated malformations (e.g., microtia, cleft palate, cardiac defects) can potentially be detected via prenatal imaging.
- Diagnostic imaging is advised for pregnancies exposed to MMF to assess fetal development.
Related Concept Videos
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:27Cryptococcal Meningitis
Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...